GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALGEN - FR0004053510 - Common Stock
2.58 EUR
-0.07 (-2.64%)
Overall ALGEN gets a fundamental rating of 5 out of 10. We evaluated ALGEN against 81 industry peers in the Biotechnology industry. Both the profitability and the financial health of ALGEN get a neutral evaluation. Nothing too spectacular is happening here. ALGEN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year ALGEN was profitable.
ALGEN had a positive operating cash flow in the past year.
In multiple years ALGEN reported negative net income over the last 5 years.
In multiple years ALGEN reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of ALGEN (3.96%) is better than 77.78% of its industry peers.
With a decent Return On Equity value of 7.06%, ALGEN is doing good in the industry, outperforming 79.01% of the companies in the same industry.
ALGEN has a better Return On Invested Capital (6.13%) than 81.48% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 13.22%.
The 3 year average ROIC (5.56%) for ALGEN is below the current ROIC(6.13%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROIC | 6.13% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 5.86%, ALGEN belongs to the best of the industry, outperforming 80.25% of the companies in the same industry.
ALGEN has a better Operating Margin (8.09%) than 77.78% of its industry peers.
ALGEN's Gross Margin of 92.34% is amongst the best of the industry. ALGEN outperforms 86.42% of its industry peers.
In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.
Compared to 1 year ago, ALGEN has less shares outstanding
The number of shares outstanding for ALGEN has been increased compared to 5 years ago.
Compared to 1 year ago, ALGEN has an improved debt to assets ratio.
2.2 Solvency
ALGEN has an Altman-Z score of 2.29. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.29, ALGEN is doing good in the industry, outperforming 67.90% of the companies in the same industry.
ALGEN has a debt to FCF ratio of 1.41. This is a very positive value and a sign of high solvency as it would only need 1.41 years to pay back of all of its debts.
ALGEN has a better Debt to FCF ratio (1.41) than 85.19% of its industry peers.
ALGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ALGEN has a Debt to Equity ratio (0.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Altman-Z | 2.29 |
ROIC/WACC0.87
WACC7.01%
2.3 Liquidity
ALGEN has a Current Ratio of 1.92. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ALGEN (1.92) is comparable to the rest of the industry.
ALGEN has a Quick Ratio of 1.81. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ALGEN (1.81) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
ALGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.41%, which is quite good.
Looking at the last year, ALGEN shows a quite strong growth in Revenue. The Revenue has grown by 10.04% in the last year.
ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
3.2 Future
ALGEN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
The Revenue is expected to grow by 10.37% on average over the next years. This is quite good.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 12.29, the valuation of ALGEN can be described as correct.
Based on the Price/Earnings ratio, ALGEN is valued cheaper than 90.12% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.41. ALGEN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.29 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALGEN is valued cheaply inside the industry as 91.36% of the companies are valued more expensively.
ALGEN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALGEN is cheaper than 93.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.4 | ||
| EV/EBITDA | 4.29 |
4.3 Compensation for Growth
ALGEN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%
5. Dividend
5.1 Amount
ALGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALGEN (12/3/2025, 7:00:00 PM)
2.58
-0.07 (-2.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners10.39%
Ins Owner ChangeN/A
Market Cap24.46M
Revenue(TTM)22.06M
Net Income(TTM)1.26M
Analysts86.67
Price Target6.02 (133.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.29 | ||
| Fwd PE | N/A | ||
| P/S | 1.14 | ||
| P/FCF | 5.4 | ||
| P/OCF | 3.54 | ||
| P/B | 1.38 | ||
| P/tB | 2.01 | ||
| EV/EBITDA | 4.29 |
EPS(TTM)0.21
EY8.14%
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.48
FCFY18.53%
OCF(TTM)0.73
OCFY28.25%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROCE | 7.62% | ||
| ROIC | 6.13% | ||
| ROICexc | 7.79% | ||
| ROICexgc | 11.35% | ||
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% | ||
| FCFM | 21.15% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 55.06% | ||
| Cap/Sales | 11.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 114.18% | ||
| Profit Quality | 360.76% | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 2.29 |
F-Score5
WACC7.01%
ROIC/WACC0.87
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y308.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1010.09%
OCF growth 3YN/A
OCF growth 5YN/A
GENOWAY SA / ALGEN.PA FAQ
Can you provide the ChartMill fundamental rating for GENOWAY SA?
ChartMill assigns a fundamental rating of 5 / 10 to ALGEN.PA.
Can you provide the valuation status for GENOWAY SA?
ChartMill assigns a valuation rating of 5 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Fairly Valued.
How profitable is GENOWAY SA (ALGEN.PA) stock?
GENOWAY SA (ALGEN.PA) has a profitability rating of 6 / 10.
How financially healthy is GENOWAY SA?
The financial health rating of GENOWAY SA (ALGEN.PA) is 6 / 10.